Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply by Authors.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: faino av. J Urol. 2020 Apr;203(4):733. doi: 10.1097/JU.0000000000000621.02. Epub 2020 Jan 17. J Urol. 2020. PMID: 31951502 No abstract available.
A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment.
Liss MA, Schenk JM, Faino AV, Newcomb LF, Boyer H, Brooks JD, Carroll PR, Dash A, Fabrizio MD, Gleave ME, Nelson PS, Neuhouser ML, Wei JT, Zheng Y, Wright JL, Lin DW, Thompson IM. Liss MA, et al. Among authors: faino av. Prostate Cancer Prostatic Dis. 2016 Dec;19(4):390-394. doi: 10.1038/pcan.2016.28. Epub 2016 Jul 19. Prostate Cancer Prostatic Dis. 2016. PMID: 27431498 Free PMC article.
Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW. Kearns JT, et al. Among authors: faino av. Eur Urol. 2018 May;73(5):706-712. doi: 10.1016/j.eururo.2018.01.016. Epub 2018 Feb 9. Eur Urol. 2018. PMID: 29433973 Free PMC article.
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Cooperberg MR, et al. Among authors: faino av. Eur Urol. 2018 Aug;74(2):211-217. doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9. Eur Urol. 2018. PMID: 29433975 Free PMC article.
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.
Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW. Kearns JT, et al. Among authors: faino av. J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065. J Urol. 2019. PMID: 30076904 Free PMC article.
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. Newcomb LF, et al. Among authors: faino av. Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-445. doi: 10.1038/s41391-018-0124-z. Epub 2019 Jan 21. Prostate Cancer Prostatic Dis. 2019. PMID: 30664734 Free PMC article.
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: faino av. J Urol. 2020 Apr;203(4):727-733. doi: 10.1097/JU.0000000000000621. Epub 2019 Oct 25. J Urol. 2020. PMID: 31651227 Free PMC article.
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
Cooperberg MR, Zheng Y, Faino AV, Newcomb LF, Zhu K, Cowan JE, Brooks JD, Dash A, Gleave ME, Martin F, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Carroll PR, Lin DW. Cooperberg MR, et al. Among authors: faino av. JAMA Oncol. 2020 Oct 1;6(10):e203187. doi: 10.1001/jamaoncol.2020.3187. Epub 2020 Oct 8. JAMA Oncol. 2020. PMID: 32852532 Free PMC article.
Reply by Authors.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: faino av. J Urol. 2021 Feb;205(2):339-340. doi: 10.1097/JU.0000000000001444. Epub 2020 Nov 6. J Urol. 2021. PMID: 33155864 No abstract available.
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort.
Waisman Malaret AJ, Chang P, Newcomb L, Faino A, Zheng Y, Zhu K, McKenney JK, Brooks JD, Dash A, Ellis WJ, Filson CP, Gleave M, Liss M, Martin FM, Morgan T, Carroll P, Nelson P, Lin DW, Wagner AA. Waisman Malaret AJ, et al. Urol Pract. 2021 Sep;8(5):576-582. doi: 10.1097/UPJ.0000000000000245. Epub 2021 Jun 25. Urol Pract. 2021. PMID: 37145399
50 results